New Blood Test Could Improve ALS Diagnostic Accuracy
A new 10-protein signature identified by researchers could offer a more accurate way to detect ALS in the future.
Updated on Oct. 28, 2026 in Stroke
Live Poll
Should medical research prioritize the development of faster diagnostic tools for incurable diseases?
Emory University researchers have identified a 10-protein blood signature capable of detecting amyotrophic lateral sclerosis (ALS) with high precision. This experimental approach outperformed current standard tests in initial testing, potentially offering a more reliable diagnostic path for patients.
Why it matters
Diagnosing ALS is often difficult because early symptoms frequently mimic other neurological conditions, leading to significant delays in care. This new blood-based test aims to improve diagnostic accuracy and speed, helping clinicians distinguish the condition from other disorders more effectively.
In a validation cohort of 144 ALS patients and 37 healthy controls, a 10-protein blood signature achieved 98.3% balanced accuracy. This performance surpassed that of neurofilament light chain testing alone, though researchers note these are preliminary findings that require further study.
The players
Emory University
A research institution that conducted the study and leads major neurological and clinical research programs.
The details
Researchers used NULISA technology to analyze over 300 neurological and inflammatory proteins in blood plasma. The identified 10-protein signature includes key markers such as NFL, NEFH, pTau-181, and VEGFA, which together provide a more comprehensive profile than single-marker tests. By analyzing these specific combinations, the signature helps differentiate ALS from other conditions by capturing a broader range of biological changes associated with the disease.
Timeline
October 28, 2026: Research findings were announced.
Health Landscape
This research utilizes NULISAseq CNS and Inflammation panels to profile blood proteins, marking a shift toward multiplex diagnostics for neurodegenerative conditions. It builds on the long-standing clinical reliance on single-marker tests by proving that multi-protein signatures offer superior sensitivity.
While this test represents a promising diagnostic tool, it is not yet available for clinical use in standard medical practices. If you or a family member are experiencing symptoms that suggest a neurological condition, discuss diagnostic options and current testing standards with a neurologist.
The takeaway
This new protein signature demonstrates that multi-marker blood testing could significantly improve the speed and accuracy of an ALS diagnosis. Individuals concerned about neurological symptoms should track their symptoms closely and consult with a specialist to discuss the most current diagnostic tests available.
Further reading
To understand the broader context of neurological diagnostic advancements, visit the Stroke section.
Source note: This article includes information reported by Financial Post.
Live Poll
Should medical research prioritize the development of faster diagnostic tools for incurable diseases?
